Citi Starts Puma Biotechnology (PBYI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts PBYI Hot Sheet
Price: $10.85 --0%
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 4 | New: 6
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 4 | New: 6
Join SI Premium – FREE
Citi initiated coverage on Puma Biotechnology (NYSE: PBYI) with a Buy rating and a price target of $123.00.
For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.
Shares of Puma Biotechnology closed at $73.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Assumes HF Sinclair (DINO) at Overweight
- Goldman Sachs Starts Sumitomo Bakelite Co Ltd. (4203:JP) at Buy
- Stephens Starts Mama’s Creations (MAMA) at Overweight
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
